Generic Medicine Info
Should be taken with food. Take immediately after meals.
Hypersensitivity to griseofulvin and penicillin. Systemic lupus erythematosus (SLE), porphyria. Severe hepatic impairment. Pregnancy.
Special Precautions
Mild to moderate hepatic impairment. Children. Lactation. Men should not father a child during and for 6 months after treatment. Patient Counselling This drug may cause drowsiness, confusion, dizziness and impaired coordination, if affected, do not drive or operate machinery. Avoid exposure to sunlight or UV sources. Spray: Avoid exposure to open flame or other source of ignition during or after application. Monitoring Parameters Monitor CBC (long-term treatment), liver and renal function. Assess for signs of severe skin reaction.
Adverse Reactions
Significant: Onset or exacerbation of SLE, photosensitivity reaction, rarely, leucopenia, granulocytopenia. Gastrointestinal disorders: Diarrhoea, dry mouth, vomiting, nausea, gastric discomfort, epigastric distress, oral candidiasis. Rarely, gastrointestinal haemorrhage. General disorders and administration site conditions: Fatigue. Nervous system disorders: Headache, dizziness, paraesthesia, impaired coordination, peripheral neuropathy. Psychiatric disorders: Confusion, insomnia. Renal and urinary disorders: Rarely, nephrosis, proteinuria. Skin and subcutaneous tissue disorders: Rash, urticaria, irritation (e.g. stinging, burning).
Potentially Fatal: Severe skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme), photosensitivity, hepatotoxicity (e.g. jaundice, elevated LFT or bilirubin).
Drug Interactions
Decreased serum concentrations of coumarin anticoagulants, oral contraceptives, ciclosporin and salicylates. Decreased serum concentrations of griseofulvin with phenylbutazone, barbiturates (e.g. phenobarbital) and other sedative and hypnotic drugs.
CIMS Class
ATC Classification
D01BA01 - griseofulvin ; Belongs to the class of antifungals for systemic use.
D01AA08 - griseofulvin ; Belongs to the class of antibiotics. Used in the topical treatment of fungal infection.
Disclaimer: This information is independently developed by CIMS based on griseofulvin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in